Stephen Su Yang1,2,3, Charles Gelinas4, Edmund Yim4, Mandy M J Li5, Kenneth Kardash6, Michelle Zhang7, Jed Lipes8. 1. Department of Anesthesia, Jewish General Hospital, McGill University, Montreal, QC, Canada. stephen.yang@mail.mcgill.ca. 2. Lady Davis Research Institute, Jewish General Hospital, McGill University, Montreal, QC, Canada. stephen.yang@mail.mcgill.ca. 3. Division of Critical Care, Jewish General Hospital, McGill University, Montreal, QC, Canada. stephen.yang@mail.mcgill.ca. 4. Department of Anesthesia, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada. 5. Department of Anesthesiology and Pain Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada. 6. Department of Anesthesia, Jewish General Hospital, McGill University, Montreal, QC, Canada. 7. Department of Radiology, McGill University Health Centre, McGill University, Montreal, QC, Canada. 8. Division of Critical Care, Jewish General Hospital, McGill University, Montreal, QC, Canada.
Abstract
PURPOSE: Dexmedetomidine is frequently used as a sedative agent for orthopedic surgery patients undergoing total hip or knee arthroplasty. Although the benefits of dexmedetomidine are well described in the literature, there is also potential for harm, especially regarding the hemodynamic effects of dexmedetomidine in the postoperative setting. METHODS: This historical cohort study included all primary unilateral total hip or knee arthroplasties conducted from April 2017 to February 2020 in a single, university-affiliated, tertiary care centre (Jewish General Hospital, Montreal, QC, Canada). We used multivariable logistic regression to analyze the predictors for postoperative hypotension, defined as a systolic blood pressure < 90 mm Hg or any systolic blood pressure while on a vasopressor infusion in the postanesthesia care unit. Models were validated using calibration and discrimination with bootstrapping technique. RESULTS: One thousand five hundred and eighty-eight patients were included in this study. Postoperative hypotension occurred in 413 (26%) patients. Statistically significant predictors for postoperative hypotension included female sex (adjusted odds ratio [aOR], 3.24; 95% confidence interval [CI], 2.29 to 4.58), a history of transient ischemic attack or cerebrovascular accident (aOR, 1.97; 95% CI, 1.04 to 3.72), and intraoperative dexmedetomidine use (aOR, 2.61; 95% CI, 1.99 to 3.42). Moreover, the risk of postoperative hypotension was approximately two times higher than baseline, with a total intraoperative dexmedetomidine dose above 50 μg (relative risk, 1.99; 95% CI, 1.63 to 2.44; P < 0.001). A higher preoperative systolic blood pressure (aOR, 0.98; 95% CI, 0.97 to 0.99) was a protective factor for postoperative hypotension. CONCLUSION: In this historical cohort study, dexmedetomidine was a strong risk factor for postoperative hypotension in total hip or knee arthroplasty patients. Dexmedetomidine, and particularly at high cumulative doses above 50 μg, should be administered judiciously in high-risk surgical patients to minimize the risk of postoperative hypotension.
PURPOSE: Dexmedetomidine is frequently used as a sedative agent for orthopedic surgery patients undergoing total hip or knee arthroplasty. Although the benefits of dexmedetomidine are well described in the literature, there is also potential for harm, especially regarding the hemodynamic effects of dexmedetomidine in the postoperative setting. METHODS: This historical cohort study included all primary unilateral total hip or knee arthroplasties conducted from April 2017 to February 2020 in a single, university-affiliated, tertiary care centre (Jewish General Hospital, Montreal, QC, Canada). We used multivariable logistic regression to analyze the predictors for postoperative hypotension, defined as a systolic blood pressure < 90 mm Hg or any systolic blood pressure while on a vasopressor infusion in the postanesthesia care unit. Models were validated using calibration and discrimination with bootstrapping technique. RESULTS: One thousand five hundred and eighty-eight patients were included in this study. Postoperative hypotension occurred in 413 (26%) patients. Statistically significant predictors for postoperative hypotension included female sex (adjusted odds ratio [aOR], 3.24; 95% confidence interval [CI], 2.29 to 4.58), a history of transient ischemic attack or cerebrovascular accident (aOR, 1.97; 95% CI, 1.04 to 3.72), and intraoperative dexmedetomidine use (aOR, 2.61; 95% CI, 1.99 to 3.42). Moreover, the risk of postoperative hypotension was approximately two times higher than baseline, with a total intraoperative dexmedetomidine dose above 50 μg (relative risk, 1.99; 95% CI, 1.63 to 2.44; P < 0.001). A higher preoperative systolic blood pressure (aOR, 0.98; 95% CI, 0.97 to 0.99) was a protective factor for postoperative hypotension. CONCLUSION: In this historical cohort study, dexmedetomidine was a strong risk factor for postoperative hypotension in total hip or knee arthroplasty patients. Dexmedetomidine, and particularly at high cumulative doses above 50 μg, should be administered judiciously in high-risk surgical patients to minimize the risk of postoperative hypotension.
Authors: Stavros G Memtsoudis; Crispiana Cozowicz; Janis Bekeris; Dace Bekere; Jiabin Liu; Ellen M Soffin; Edward R Mariano; Rebecca L Johnson; Mary J Hargett; Bradley H Lee; Pamela Wendel; Mark Brouillette; George Go; Sang J Kim; Lila Baaklini; Douglas Wetmore; Genewoo Hong; Rie Goto; Bridget Jivanelli; Eriphyli Argyra; Michael J Barrington; Alain Borgeat; Jose De Andres; Nabil M Elkassabany; Philippe E Gautier; Peter Gerner; Alejandro Gonzalez Della Valle; Enrique Goytizolo; Paul Kessler; Sandra L Kopp; Patricia Lavand'Homme; Catherine H MacLean; Carlos B Mantilla; Daniel MacIsaac; Alexander McLawhorn; Joseph M Neal; Michael Parks; Javad Parvizi; Lukas Pichler; Jashvant Poeran; Lazaros A Poultsides; Brian D Sites; Otto Stundner; Eric C Sun; Eugene R Viscusi; Effrossyni G Votta-Velis; Christopher L Wu; Jacques T Ya Deau; Nigel E Sharrock Journal: Br J Anaesth Date: 2019-07-24 Impact factor: 9.166
Authors: Pavel S Roshanov; Bram Rochwerg; Ameen Patel; Omid Salehian; Emmanuelle Duceppe; Emilie P Belley-Côté; Gordon H Guyatt; Daniel I Sessler; Yannick Le Manach; Flavia K Borges; Vikas Tandon; Andrew Worster; Alexandra Thompson; Mithin Koshy; Breagh Devereaux; Frederick A Spencer; Robert D Sanders; Erin N Sloan; Erin E Morley; James Paul; Karen E Raymer; Zubin Punthakee; P J Devereaux Journal: Anesthesiology Date: 2017-01 Impact factor: 7.892
Authors: Jeremy Cheuk Kin Sin; Alexis Tabah; Matthys J J Campher; Kevin B Laupland; Victoria A Eley Journal: Anesth Analg Date: 2022-01-27 Impact factor: 5.108
Authors: Maud A S Weerink; Michel M R F Struys; Laura N Hannivoort; Clemens R M Barends; Anthony R Absalom; Pieter Colin Journal: Clin Pharmacokinet Date: 2017-08 Impact factor: 6.447